Name: 研究發現，華銳風電的疫苗是 "有吸引力的選擇 (Sinovac's vaccine 'attractive option,' study finds)
Uploaded: 2020-11-19T18:15:40.000Z
Duration: 1 min 48 s

關係子句

the cove in 19 vaccine developed by Chinese companies, See Novak Biotech was found to trigger a quick immune response, according to preliminary trial results published on Wednesday, although the level of antibodies produced was lower than in people who had recovered from the disease, The findings were published in a peer reviewed paper and medical journal, The Lancet Infectious Diseases.

灣在 19 疫苗開發的中國公司，見諾瓦克生物技術公司被發現觸發快速的免疫反應，根據初步試驗結果發表在週三，雖然產生的抗體水準低於人已從疾病中恢復，調查結果發表在同行評審論文和醫學雜誌，柳葉刀傳染病。

It looked at the results in Phase one and phase two clinical trials in China involving more than 700 participants.

它考察了在中國進行的涉及700多名參與者的一期和二期臨床試驗的結果。

In a statement released alongside the study, one of the authors said that the sea Novak vaccine, called Corona Vac, is capable of inducing a quick antibody response within four weeks of immunization.

在這項研究的同時發佈的一份聲明中，其中一位作者表示，名為 "Corona Vac "的海諾威疫苗能夠在免疫後四周內快速誘導抗體反應。

One researcher involved called the vaccine and attractive option because it could be stored at normal fridge temperatures and may remain stable for up to three years.

一位參與的研究人員稱這種疫苗和有吸引力的選擇，因為它可以在正常的冰箱溫度下儲存，並可能保持穩定長達3年。

This differs from the vaccine by Pfizer, which can only be kept in a normal fridge for up to five days, or Madonna's, which is expected to last for 30 days at normal fridge temperatures.

這與輝瑞公司的疫苗不同，輝瑞公司的疫苗最多隻能在普通冰箱中保存5天，而麥當勞的疫苗在普通冰箱溫度下預計可保存30天。

But researchers stressed phase three trials would be crucial to determining of the vaccine is sufficient protecting people from the coronavirus infection.

但研究人員強調，階段性的三個試驗將是關鍵，以確定的疫苗是足以保護人們免受冠狀病毒感染。

One professor from Johns Hopkins University not involved in the study also warned that the results must be interpreted with caution.

一位沒有參與研究的約翰-霍普金斯大學教授也警告說，必須謹慎解讀這一結果。

Until then, see Novak is currently running three phase three trials and Indonesia, Brazil and Turkey.

在此之前，見諾瓦克目前正在進行三期試驗和印尼、巴西和土耳其。

 Four other experimental vaccines developed in China are undergoing late stage trials to determine their effectiveness and preventing COVE in 19. 

中國研發的另外四種實驗性疫苗正在進行後期試驗，以確定其有效性，並在19中預防COVE。